XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases.
This week, XVIVO’s Founder and Creative Director, Michael Astrachan, spoke on an invited panel of guests at UCONN’s Science Salon to discuss “Seeing Things: Virtual Reality Hits Mainstream.” Michael was honored to speak alongside the other accomplished panelists: Patrick Belinger,
To kick-off the New Year, we’re launching a fresh new showreel for XVIVO.
2018 was an exciting and rewarding year for the team at XVIVO Scientific Animation. We delved into new topics, such as neuroendocrine tumors and ciliary motility, we
XVIVO is in the holiday spirit! This past Saturday, the team at XVIVO got the opportunity to relax, unwind and celebrate another successful year together. Our team looked dapper and dressed up for the holiday season!
The NIH Somatic Cell Genome Editing program is supporting development of new tools and tests that may one day bring more gene therapies to patients.
What if a disease could be treated by diving into a cell to edit the